INTRODUCTION
Medulloblastoma (MB) is the most common malignant brain tumor in children. 1 Intensive therapy-including surgery, craniospinal radiation and high-dose chemotherapy-has improved 5-year survival rates, 2 but almost a third of MB patients still die from their disease, and patients who survive suffer severe long-term side effects that affect their quality of life. 3 Thus, safer and more effective therapies are needed for this disease.
In recent years, targeted therapies have begun to be evaluated in patients with MB. For example, with the recognition that a subset of MBs results from mutations in the Sonic hedgehog (SHH) pathway, 4 antagonists of Smoothened (SMO), an activator of the pathway, have advanced into clinical trials for the disease. Although initial reports suggested that these agents can inhibit tumor growth, 5 as with many targeted therapies, resistance develops quickly. 6 Moreover, patients who have SHH pathway mutations downstream of SMO do not respond to these agents at all. 7 Thus, even for SHH-driven MBs, additional approaches are necessary.
Finding novel therapeutic targets for MB depends on identification of genes that are critical for tumor growth and survival.
Survivin (also known as baculoviral inhibitor of apoptosis repeatcontaining 5, or BIRC5) is a member of the inhibitor of apoptosis protein family that regulates both cell cycle progression and cell survival. 8, 9 Survivin is expressed in many human cancers, and its expression is correlated with poor clinical outcome in non-smallcell lung cancer, 10 breast cancer, 11 leukemia, 12,13 neuroblastoma 14 and glioma. 15 Because of its high expression in tumors and minimal expression in most adult tissues, 16 a number of approaches have been developed to inhibit its expression and function. These include small-molecule antagonists, antisense oligonucleotides and immunotherapy. [17] [18] [19] [20] [21] Some of these approaches are in clinical trials for numerous cancers, including prostate cancer, 22 melanoma, 23, 24 breast cancer, 25 and non-smallcell lung cancer. 25, 26 Survivin has not been studied extensively in the context of MB. Although some studies have suggested that elevated expression is linked to poor prognosis, [27] [28] [29] little is known about its role in MB growth and survival. Using an animal model of SHH-driven MB, we now show that Survivin is highly expressed in tumors and absent from normal adult cerebellum. Moreover, through both genetic deletion and pharmacologic inhibition, we demonstrate that Survivin is critical for proliferation and survival of mouse and human SHH-driven MB cells. Finally, Survivin antagonists impair growth of MB in vivo, highlighting the potential of Survivin as a therapeutic target in patients with MB.
RESULTS

Survivin is highly expressed in MBs from Ptch mutant mice
To determine whether Survivin could represent a target in SHHdriven MB, we isolated RNA from Ptch mutant tumors and examined survivin expression using quantitative reverse-transcription PCR (qRT-PCR). High levels of survivin were detected in all tumors and in granule neuron precursors (GNPs), the progenitors from which these tumors are thought to arise 30 ( Figure 1a ). Importantly, expression could not be detected in normal adult cerebellum. Similar results were seen when Survivin protein was examined by immunoblotting ( Figure 1b) . Staining of tissue sections revealed Survivin expression primarily in the nuclei of tumor cells (abrogated by blocking peptide; Figure 1d ), and minimal staining in normal adult cerebellum (Figures 1c-f ). These data indicate that Survivin is highly expressed in Ptch mutant tumors, raising the possibility that it might have an important role in tumor growth or maintenance.
Survivin is critical for MB cell proliferation and cell cycle progression To investigate the importance of Survivin for the growth of MB cells, we first used a genetic approach. Survivin fl/fl mice, 31 in which the survivin gene is flanked by loxP sites, were crossed with Ptch +/ − mice, to generate tumors in which survivin can be deleted by Cre recombinase. We confirmed efficient deletion of survivin by isolating tumor cells from Survivin fl/fl ;Ptch +/ − (SP) mice and infecting them with Cre retroviruses. After 48 h, survivin expression was significantly reduced (by 82%) in Cre-infected cells compared with control (GFP-infected) cells (Figure 2a) . We then looked at the effect of survivin loss on proliferation. After Cre-mediated deletion of survivin from SP tumor cells, thymidine incorporation was decreased by almost 90% (Figure 2b) . Importantly, when tumor cells from Survivin WT mice were infected with Cre viruses, there was no appreciable difference in proliferation compared with control cells (Figure 2c ), indicating that the decreased thymidine incorporation observed in SP tumor cells was not because of nonspecific toxicity of the Cre virus. To address whether loss of survivin affects cell cycle progression, we isolated cells from SP tumors, infected them with Cre or GFP viruses and performed cell cycle analysis (Figures 2d and e) . Survivin deletion led to a marked accumulation of cells in the G2/M phases of the cell cycle (39% of Figure 1 . Survivin is expressed in Ptch mutant tumors. RNA and protein from Ptch mutant MB cells, P7 GNPs and adult cerebellum were analyzed for Survivin expression using qRT-PCR (a) and by western blotting (b). Survivin is highly expressed in tumors and GNPs, but not in adult cerebellum. Error bars in (a) represent 95% confidence interval calculated using sum of the squares method (P o0.02 by ANOVA and post hoc Student's t-test). (c-f) Tissue sections from Ptch mutant tumor and normal adult cerebellum were stained with anti-Survivin antibodies alone (c and e) or with anti-Survivin antibodies that were preincubated for 30 min with Survivin-blocking peptide (d and f). Survivin is highly expressed in tumor cells with minimal expression in adult cerebellum. Inset in (c) is × 4 magnification of positive staining. Scale bars, 50 μM. Data are representative of three experiments.
Cre-infected cells vs 9.5% of control cells in G2/M). Taken together, these data demonstrate that Survivin is necessary for proliferation and cell cycle progression of MB cells.
Survivin antagonists inhibit MB cell proliferation and promote apoptosis Given the importance of Survivin for MB proliferation, we hypothesized that pharmacologic agents that inhibit Survivin expression or function might interfere with tumor growth. To test this, we obtained several small-molecule Survivin antagonists: YM155 is an inhibitor of survivin transcription, 32 whereas S12 and LLP3 bind directly to Survivin protein and interfere with its function. 33, 34 To test the ability of YM155 to inhibit survivin expression in Ptch mutant MB cells, we treated cells with the drug for 48 h, isolated RNA and performed qRT-PCR for survivin. YM155 markedly decreased survivin expression even at a concentration of 10 nM (Supplementary Figure 1A) . Similarly, loss of Survivin was detected at the protein level using western blotting (Supplementary Figure 1B) . These data suggest that YM155 effectively inhibits survivin expression in Ptch mutant MB cells. To test the effects of Survivin antagonists on MB growth, we treated tumor cells with these agents and analyzed the percentage of cells expressing the proliferation marker Ki67. Consistent with our genetic results, inhibition of Survivin using either YM155 or S12 caused a significant decrease in the number of Ki67+ cells compared with treatment with vehicle (dimethyl sulfoxide (DMSO)) (Figures 3a-d) . Additionally, we saw a dosedependent decrease in thymidine incorporation after treatment with YM155, S12 or LLP3 (Figures 3e, f and Supplementary Figure  2 ). These data suggest that Survivin antagonists effectively inhibit MB growth in vitro.
To determine whether Survivin antagonists also cause cell cycle arrest in MB cells, we performed cell cycle analysis. After 24 h, cells treated with S12 showed a significant accumulation in the G2/M phase (56%) compared with cells treated with vehicle (12%) (Figures 4a and c) . G2/M accumulation was also seen at 36 h (52%) (Figures 4b and d) . In contrast to S12, YM155 decreased the percentage of cells in G2/M (7%), with a concomitant increase in the S phase (from 15 to 20% at 24 h) (Figures 4e-h ). Notwithstanding these differences, our data demonstrate that both Survivin antagonists alter normal cell cycle progression of MB cells.
In addition to its role in regulating cell cycle progression, Survivin has been suggested to function as an inhibitor of apoptosis. To determine if Survivin inhibition promotes MB cell apoptosis, tumor cells were treated with Survivin antagonists and then stained with Annexin-V and propidium iodide. As shown in Figures 4i-k, antagonists increased the percentage of apoptotic (Annexin-V+) tumor cells from 21% (after DMSO treatment) to 62% (S12) or 59% (YM155). These data show that Survivin antagonists are not merely cytostatic, but can promote apoptosis of tumor cells as well.
To verify that Survivin antagonists were not inducing nonspecific toxicity, we tested their effects on GNPs, which express survivin (see Figure 1) , and postmitotic neurons, which do not. Treatment of GNPs with YM155 or S12 caused a dose-dependent increase in the percentage of dead cells (as measured by EthD1 staining). In contrast, survival of postmitotic neurons was not affected by treatment with Survivin antagonists (Supplementary Figures 3A and B) . These data suggest that Survivin antagonists induce death of Survivin-expressing cells but are not toxic to normal cerebellar neurons. Survivin antagonists cooperate with radiation and SHH antagonists Among the major drawbacks of current MB therapy are the devastating side effects of radiation. 35, 36 Since recent studies have suggested that YM155 can enhance the efficacy of radiotherapy against non-small-cell lung cancer, 37 we hypothesized that combining radiation and Survivin antagonists might be effective for MB as well. To test this, we performed thymidine incorporation assays on tumor cells treated with Survivin antagonists for 24 h followed by exposure to varying doses of radiation ( Figure 5a ). Treatment with suboptimal doses of YM155 and S12 alone resulted in a small decrease in proliferation. The combination of Survivin antagonists and 0.25 Gy radiation markedly decreased tumor cell proliferation compared with radiation alone. The level of inhibition achieved with the combination treatment was equivalent to that achieved by doubling the radiation dose. These data suggest that Survivin antagonists can enhance the effects of radiation on MB cells, and raise the possibility that these agents might allow reduction in the doses of radiation used for therapy.
In addition to conventional therapy, targeted therapies have begun to be evaluated for treatment of MB. For SHH-associated tumors, NVP-LDE225, a small-molecule antagonist of SMO, has shown some efficacy in animal models as well as in patients. 38, 39 To test whether Survivin antagonists increase the efficacy of SHH antagonists, we treated Ptch mutant tumor cells with various concentrations of LDE225 alone or in combination with 10 μg/ml S12 (Figure 5b ). LDE225 alone had an IC 50 (half-maximal inhibitory concentration) of 5.5 nM (range: 3-8.5 nM), whereas the combination of LDE225 and S12 markedly decreased the IC 50 to 0.04 nM (range: 0.04-2 nM). Similarly, exposure to 20 nM YM155 decreased the IC 50 of LDE225 (from 13.5 to 6.4 nM). These data suggest that Survivin antagonists significantly enhance growth inhibition by LDE225.
Survivin antagonists inhibit growth of human SHH-driven MB cells The studies described above focused on murine SHH-associated MB. To determine whether human SHH-driven MB cells also respond to Survivin antagonists, we used patient-derived xenografts (PDXs) from SHH-driven tumors. Real-time RT-PCR analysis revealed that PDX cells express high levels of survivin (Supplementary Figure 4) . Treatment of PDX cells with Survivin antagonists in vitro led to significant decreases in [ 3 H]thymidine incorporation (Figures 6a-c) . Tumor cells were also treated with the SMO antagonist LDE225. Notably, the PDX line with a mutation upstream of SMO 7 (DMB-012) was responsive to LDE225 (Figure 6a (left panel) and Markant et al. 40 ), whereas the lines with mutations downstream of SMO 40, 41 (RCMB-018 and ICb-984MB) were resistant (Figures 6b and c) . In contrast, all three lines responded robustly to YM155 and high-dose S12. These data suggest that Survivin antagonists can inhibit the growth of human SHH-driven MBs and that they may be useful for treating tumors that are resistant to SMO antagonists.
Survivin antagonists inhibit MB growth in vivo
Given the ability of Survivin antagonists to inhibit proliferation and promote apoptosis of tumor cells in vitro, we questioned whether inhibiting Survivin could prevent tumor growth in vivo. Unfortunately, published reports 42 as well as our own preliminary studies suggested that these antagonists do not accumulate in the brain or intracranial tumors. Therefore, Ptch mutant tumors were implanted into the flanks of Nu/Nu mice and treated with YM155 or vehicle. Intratumoral injections of YM155 significantly decreased tumor growth compared with treatment with vehicle ( Figure 7a ). Tumors harvested after 6 weeks of treatment were much smaller than those in the vehicle-treated mice (Figures 7b  and c) . We also tested whether systemic treatment with YM155 could inhibit tumor growth in vivo; since YM155 has a short H]thymidine for 12 h to measure proliferation. Treatment with either antagonist decreased proliferation in a dose-dependent manner (P o0.02 for all YM155 and S12 doses except 5 μg/ml S12, which was not significant (NS)). Ki67+ percentages in (a) were averaged from six images for each treatment. Data in (e and f) represent mean ± s.d. and are representative of six experiments. Statistics were calculated by ANOVA and post hoc Student's t-tests.
half-life, we used osmotic pumps for delivery. 20, 32, 43 Nu/Nu mice bearing Ptch mutant flank tumors were implanted with microosmotic pumps to continuously infuse YM155 or vehicle (saline) for 3 weeks. Tumors in mice with YM155-containing pumps grew significantly less than those in mice with vehicle pumps (Figures  7d-f) . These data suggest that Survivin antagonists can potently inhibit MB growth in vivo.
DISCUSSION
Previous studies have shown that Survivin is expressed in human MB, and that its expression is correlated with poor outcome. To study the role of Survivin in MB growth and survival, we used a mouse model of MB driven by activation of the SHH pathway. Our studies demonstrate that Survivin is highly expressed in SHHdriven MB and that genetic and pharmacologic inhibition of Survivin impedes growth of MB cells in vitro and in vivo.
Our initial studies demonstrated that Survivin is expressed at high levels in Ptch mutant MB cells and not in normal adult cerebellum, suggesting that it might represent a cancer-selective target. To test the functional importance of Survivin in MB cells, we used Cre viruses to delete Survivin from Survivin fl/fl ;Ptch +/ − tumor cells. Loss of Survivin resulted in markedly decreased proliferation and arrest in the G2/M phases of the cell cycle. These results are consistent with the function of Survivin as a member of the chromosomal passenger complex, which is critical for alignment of chromosomes during metaphase and for successful cell cleavage. 44, 45 In addition, previous studies have shown that loss of Survivin leads to aberrant mitosis, centrosome amplification and failed cytokinesis in a number of cancers, including glioma and cervical cancer. 46, 47 Thus, in MB as in other tumors, Survivin seems to be critical for normal proliferation and cell cycle progression.
To evaluate Survivin's utility as a therapeutic target, we used small-molecule antagonists. Consistent with our genetic studies, Survivin antagonists significantly decreased proliferation and altered cell cycle progression. Interestingly, while S12 treatment caused accumulation of cells in the G2/M phase (similar to survivin deletion), YM155 caused cells to accumulate in the S phase. This observation is consistent with previous studies that demonstrated YM155 treatment can cause a loss of new DNA synthesis and concomitant stall in the S phase. 48 This discrepancy between S12 and YM155 could be because of differences in the kinetics or degree of Survivin inhibition induced by these drugs. Alternatively, it could result from differences in the mechanisms by which the drugs act: whereas S12 binds directly to Survivin protein, 33 YM155 inhibits survivin expression by disrupting ILF3/NF110 complexes 49, 50 or Sp1 binding at the survivin promoter. 51 Thus, in addition to potently decreasing survivin expression (see Nakahara et al. 32 and Supplementary Figure 1 ), YM155 may also alter the expression of other genes that regulate cell cycle progression (e.g. cyclin D1, p27), 52, 53 and thereby cause arrest at earlier stages of the cycle. Nonetheless, the fact that genetic deletion and several small-molecule inhibitors all interfere with cell cycle progression in Ptch mutant tumor cells strongly supports the notion that Survivin is required for this process in SHHdriven MB.
In addition to their effects on the cell cycle, Survivin antagonists also increased the percentage of MB cells undergoing apoptosis. It remains unclear whether loss of Survivin function causes apoptosis directly or as a consequence of cell cycle arrest. Analysis of Annexin+ cells after treatment with Survivin antagonists showed that apoptosis is not detectable until 36 h, whereas cell cycle inhibition is observed by 12-24 h. These results are consistent with the notion that apoptosis occurs secondary to cell cycle arrest. The fact that Survivin antagonists not only inhibit proliferation but also cause death of tumor cells may make them potent therapeutic agents for MB.
Previous studies of glioma and other cancers have suggested that targeting Survivin can enhance the effects of radiation and chemotherapy. 20, 37, [54] [55] [56] [57] [58] [59] In agreement with these data, we found that Survivin antagonists significantly enhanced the sensitivity of MB cells to radiation. Combining low-dose radiation (0.25 Gy) with S12 or YM155 was as effective at inhibiting tumor growth as doubling the dose of radiation. These data suggest that addition of Survivin antagonists may allow children to be treated with lower doses of radiation without decreasing therapeutic benefits. The approach could markedly reduce treatment-related side effects and improve the long-term quality of life of MB patients.
A major advance in the treatment of SHH-driven MB has been the development of SMO antagonists. However, one drawback of these agents is the swift acquisition of resistance to the drug and tumor recurrence. Our studies show that combining LDE225 and Survivin antagonists significantly enhanced inhibition of proliferation compared with either drug alone. Although in these studies we focused on cotreatment, it would be interesting to look at the ability of Survivin antagonists to overcome LDE225 resistance. In this context, it is notable that in non-small-cell lung cancer, downregulation of Survivin by either siRNA or treatment with YM155 reverses Erlotinib resistance. 60 It is also important to note that LDE225 and other SHH antagonists work at the level of SMO, and are thus ineffective for patients with mutations downstream in the SHH pathway. 7 We show that human PDX cells with such downstream mutations are still sensitive to inhibition by Survivin antagonists. In addition, our preliminary studies suggest that that YM155 can inhibit growth of non-SHH-associated MB cells (data not shown). These studies raise the possibility that Survivin may be a therapeutic target for a broad spectrum of MB patients.
Lastly, we have shown that YM155 can inhibit tumor growth in vivo, either by direct intratumoral injection or systemic administration. These data strongly suggest that targeting Survivin could be an effective approach for treating MB. Unfortunately, pharmacokinetic studies by our lab and others (Minematsu et al. 42 and data not shown) suggest that the Survivin antagonists we . Survivin antagonists inhibit proliferation of human SHH-driven MB cells. Cells isolated from LDE225-sensitive xenograft DMB012 (a) and LDE-insensitive xenografts RCMB018 (b) and ICb-984MB (c) were treated for 48 h with DMSO, LDE225, YM155 or S12 and analyzed for thymidine incorporation following a 12-16 h pulse. All tumor cells were sensitive to YM155 inhibition and high-dose S12 treatment (DMB012, Po0.01 for all doses including LDE225, RCM018 and ICb-984MB, P o0.03 for YM155 and 10 μg/ml S12, while LDE and 20 μg/ml S12 were not significant with P40.08). , mice were split into two cohorts and treatment was started. For (a-c), tumors were treated with vehicle (20% DMSO in saline) or YM155 (20 μM) via intratumoral (IT) injection two times a week (vehicle, n = 5; YM155, n = 6). For (d-f), mice were treated with vehicle (saline) or YM155 (10 mg/kg per day) via micro-osmotic pump (vehicle, n = 6; YM155, n = 5). Caliper measurements were made two times a week to monitor tumor growth (a and d) and resulting tumors were collected, photographed (b and e) and weighed (c and f). Experiments were repeated two (a-c) and three times (d-f), respectively. Both intratumoral and systemic treatment with YM155 decreased tumor size over time compared with vehicle control (P o0.02 for both IT and pump YM155 treated tumor weights by ANOVA with post hoc Student's t-test). Error bars represent s.e.m.
have tested do not show significant accumulation in the brain or in intracranial tumors. Thus, chemical modification of these agents or alternative modes of delivery (e.g. convection enhanced 61, 62 or intrathecal delivery 63, 64 ) may be necessary to make these agents useful for treatment of MB and other brain tumors. (MERP) mice have been described previously. P4 MERP pups were gavaged with 0.8 g/40 μl of tamoxifen (T-5648; Sigma, St Louis, MO, USA) in corn oil to generate tumors. Tumors from Ptch +/ − and MERP mice were used for experiments. To allow for deletion of survivin in tumor cells, Survivin fl/fl mice were crossed with Ptch +/ − mice to generate the SP line. CD-1 Nu/Nu mice were from Charles River Laboratories (Wilmington, MA, USA). P7 wild-type C57BL/6 pups were obtained from the SBMRI Animal Facility (La Jolla, CA, USA). All mice were maintained in the animal facility, and experiments were performed in accordance with national guidelines and regulations, and with the approval of the SBMRI Institutional Animal Care and Use Committee.
MATERIALS AND METHODS Mice
Cell isolation and in vitro culture
GNPs were isolated from P7 cerebellum and tumors from adult cerebellum as previously described. 30, 68 Briefly, tissue was digested in a solution containing 10 U/ml papain (Worthington Biochemical Corporation, Lakewood, NJ, USA) and 250 U/ml DNase (Sigma), and triturated to obtain a single-cell suspension. Cells were spun through a 35-65% Percoll gradient (GE Healthcare, Uppsala, Sweden) to purify GNPs and tumor cells. Cells were cultured in NB/NS-21 media (Neurobasal media, 1 mM sodium pyruvate, 2 mM L-glut, penicillin/streptomycin and NS-21 supplement, plus 1% FBS; Invitrogen, Grand Island, NY, USA) on growth factor-reduced (GFR) Matrigel-coated plates (1:50 in NB/NS-21; BD Biosciences, San Diego, CA, USA).
Real-time RT-PCR
For the analysis of survivin expression, mRNA was isolated from cells and tissues using an RNAeasy Plus Mini Kit (Qiagen Inc., Valencia, CA, USA). One-step quantitative reverse transcription-PCR reactions were performed in triplicate using QuantiTech RT mix (Qiagen) on the Bio-Rad C1000 Thermocycler and CFX96 System (Bio-Rad Laboratories, Hercules, CA, USA). Duplicate reactions were prepared without reverse transcriptase to confirm the absence of genomic DNA contamination. Relative gene expression was calculated using the ΔΔCT method and normalized to actin. The 95% confidence intervals for each sample were calculated using the sum of the squares method. To evaluate the efficiency of survivin deletion by Cre infection, SP tumor cells were isolated, infected with Cre-IRES-GFP or GFP retroviruses for 48 h, sorted for GFP expression and analyzed as outlined above.
Immunohistochemistry
For staining of paraffin-embedded tissue, animals were perfused with phosphate-buffered saline followed by 4% paraformaldehyde (Affymetrix; cat. no. 19943, Cleveland, OH, USA). Cerebella were removed, fixed in 4% paraformaldehyde overnight and delivered to the SBMRI Histology Shared Resource for embedding, antigen retrieval and staining. Sections were stained either with anti-Survivin antibodies (Cell Signaling Technology, Danvers, MA, USA; cat. no. 2808S) alone or anti-Survivin antibodies preincubated with Survivin blocking peptides (Cell Signaling Technology; cat. no. 1037).
Cell lysis and western blotting
To evaluate Survivin expression, tumor cells, GNPs and adult cerebellum were lysed in RIPA buffer (Millipore, Billerica, MA, USA). Protein was quantitated using the Bio-Rad protein assay. Equal amounts of protein were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, blocked with 5% bovine serum albumin (Sigma) in Tris-buffered saline with 0.1% Tween-20 and stained with anti-Survivin or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibodies overnight (1:1000; Cell Signaling Technology; cat. no. 2808S, 5174) followed by anti-rabbit horse radish peroxidase-conjugated secondary antibody (1:2000; Cell Signaling Technology; cat. no. 7074S). Proteins were visualized by incubating with Pierce ECL plus (Thermo Fisher Scientific, Rockford, IL, USA). To evaluate Survivin expression after YM155 treatment, tumor cells were plated in 6-well plates at a density of 6-8 × 10 6 cells per well and treated with 1 μM YM155 or 0.1% DMSO (Fisher Scientific Inc., San Diego, CA, USA) for 24 h and processed as described above.
Analysis of proliferation, cell cycle and apoptosis
To analyze the effects of Survivin loss, cells were isolated from SP tumors and infected with Cre-IRES-GFP or GFP retroviruses (murine stem cell virus, 1:5 in media). To assess the effects of pharmacologic inhibition of Survivin, Ptch mutant tumor cells were treated with YM155 (Selleck Chemicals, Houston, TX, USA), S12, 33 LLP3 34 or DMSO (Fisher Scientific) at the indicated concentrations.
Ki67 staining. Cells were plated in GFR Matrigel-coated chamber slides at a density of 0.2 × 10 6 cells per well and treated with DMSO or antagonists for 24 h. Cells were fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 in phosphate-buffered saline (Aqua Solutions, Deer Park, TX, USA) and blocked with 10% goat serum (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA) before staining with anti-Ki67 (BD Biosciences; cat. no. 556003) and 4′,6-diamidino-2-phenylindole (Invitrogen). Six representative images from each treatment were collected using the Zeiss LSM-700 confocal microscope (Zeiss, Goettingen, Germany), and Ki67+ percentages were calculated using the ImageJ software (NIH, Bethesda, MD, USA).
Thymidine incorporation. Cells were plated in GFR Matrigel-coated 96-well plates at a density of 2 × 10 5 cells per well and treated with either virus or antagonists for 48 h in triplicate wells before being pulsed with methyl-[ Live/dead assay. To address toxicity of YM155, GNPs were isolated from WT P7 pups and plated in two GFR Matrigel-coated 96-well plates at a density of 0.2 × 10 6 cells per well for each experiment. One plate was maintained in proliferation media consisting of NB/NS-21-and SHHcontaining supernatant (1:5 in media) and treated with either DMSO or various doses of YM155 and S12 with each condition in triplicate wells. After 48 h, cell viability was analyzed using the LIVE/DEAD Viability/ Cytotoxicity Kit (Invitrogen). Briefly, cells were stained with 4 μM EthD1 for 40 min and fluorescence emission (645 nM) was measured using a Tecan Infinite M200 Microplate Reader (Tecan, Morrisville, NC, USA). The second plate was maintained in differentiation media (NB/NS-21 containing 25 mM glucose and 25 mM potassium chloride) for 5 days to produce postmitotic neurons. Cells were then treated with DMSO or corresponding doses of YM155 and cell viability was evaluated after 48 h.
Radiation and LDE225 treatment
To measure effects of inhibitors in combination with radiation, tumor cells were plated in 96-well plates at a density of 0.2 × 10 6 cells per well and cultured in the presence of DMSO, 50 nM YM155 or 10 μg/ml S12. After 24 h, cells were subjected to 0, 0.25 or 0.5 Gy radiation using a Gammacell 40 Exactor (low-dose cesium 137 irradiator; Best Theratronics Ltd, Ottawa, ON, Canada). Cells were cultured for an additional 24 h, and [methyl- 3 H] thymidine assays were performed as described above.
To measure effects of inhibitors in combination with the SHH antagonist NVP-LDE225 (Selleck Chemicals; S2151), tumor cells were plated in 96-well plates at a density of 0.2 × 10 6 cells per well and cultured with increasing doses of LDE225 or a single dose of Survivin antagonist (10 μg/ml S12 and 20 nM YM255) alone or in combination with LDE225 as indicated. Cells were cultured for 48 h and [methyl-3 H]thymidine assays were performed as described above.
Human tumor isolation, propagation and classification Human MB tissue for PDXs was obtained from surgical resection of tumors at Duke University Medical Center (Durham, NC, USA), Rady Children's Hospital (San Diego, CA, USA) or Texas Children's Cancer Center (Houston, TX, USA). All procedures using human tissue were approved by the Institutional Review Boards of the respective institutions. Upon retrieval, the tissue was mechanically dissociated into a single-cell suspension, and then immediately injected into the cerebella of NSG mice. When mice showed signs of MB, tumors were again dissociated into single-cell suspensions and retransplanted back into the cerebella of naive hosts to establish a propagated line for each PDX. Molecular classification of human tumors was previously described. 7, 40, 41 Flank tumor implantation and in vivo antagonist treatment Cells isolated from tumors were resuspended 1:1 in NB/NS-21 media and GFR Matrigel. One hundred microliters of cell suspension (6-7 × 10 6 cells) was injected subcutaneously into the flanks of 5-8-week-old CD-1 Nu/Nu mice. Tumor growth was monitored using calipers and tumor volume was calculated using the formula 0.52 × length × width 2 . Treatment was initiated when tumors reached~100 mm 3 . For intratumoral injections, tumors were injected two times a week with YM155 (20 μM final concentration) or vehicle (20% DMSO in saline). For systemic treatments, mice were treated with 10 mg/kg per day YM155 or saline by subcutaneous micro-osmotic pump (Alzet, model D2004, Cupertino, CA, USA). Experimental treatments were continued until control tumors reached maximum size of 2000 mm 3 , at which point tumors were collected for analysis.
Statistics
Unless otherwise indicated, statistics were calculated by analysis of variance (ANOVA) with post hoc Student's t-test. P-values o0.05 were considered significant and marked with asterisks where appropriate.
